Ind-Swift Laboratories' Q1 FY 2025-26 Quarterly Results

Result Summary

• Ind-Swift Laboratories Ltd reported a 60.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 277.6%.
• Its expenses for the quarter were down by 63.7% QoQ and up 262.2% YoY.
• The net profit decreased 96.3% QoQ and increased 833.0% YoY.
• The earnings per share (EPS) of Ind-Swift Laboratories Ltd stood at 1.2 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ind-Swift Laboratories Ltd is a pharmaceutical company primarily engaged in the production of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates within the pharmaceutical industry, focusing on research, development, and manufacturing of drugs. It caters to both domestic and international markets, providing a range of therapeutic solutions. There are no specific recent major developments available in the provided data. The company is known for its commitment to quality and compliance with global regulatory standards, enabling it to maintain a strong presence in the pharmaceutical sector.

Revenue

The total income for Ind-Swift Laboratories Ltd in Q1FY26 amounted to ₹167.32 crores, reflecting a significant decrease of 60.0% compared to the previous quarter (Q4FY25), where it stood at ₹418.59 crores. Year-over-year, there was a substantial increase of 277.6% from ₹44.31 crores in Q1FY25. This quarterly decline in revenue may suggest variability in sales or other income components, while the annual growth indicates a considerable expansion in revenue streams over the year.

Profitability

In terms of profitability, the company reported a profit before tax of ₹10.35 crores for Q1FY26, a drastic reduction of 97.2% from ₹373.34 crores in Q4FY25. Year-over-year, this represents a significant increase of 956.1% from ₹0.98 crores in Q1FY25. The profit after tax for Q1FY26 was ₹8.77 crores, down by 96.3% from the previous quarter's ₹238.82 crores, yet a remarkable rise of 833.0% compared to ₹0.94 crores in Q1FY25. The earnings per share also reflected these trends, with a value of ₹1.20 in Q1FY26, declining by 97.0% from the last quarter but increasing by 500.0% year-over-year.

Operating Metrics

Total expenses for Ind-Swift Laboratories Ltd in Q1FY26 were ₹156.96 crores, which marks a decrease of 63.7% from Q4FY25's expenses of ₹431.84 crores. Compared to Q1FY25, there was an increase of 262.2% from ₹43.33 crores. The tax expense for Q1FY26 was ₹1.71 crores, showing a significant drop of 98.7% from the last quarter's ₹134.47 crores, while year-over-year, it shifted from a negative tax of ₹-0.03 crores, resulting in a dramatic change of -5800.0%. These figures illustrate the company's operational cost dynamics and tax liabilities over the specified periods.